Amyloid Imaging of Dutch-type Hereditary Cerebral Amyloid Angiopathy Carriers
Overview
Authors
Affiliations
Objective: To determine whether amyloid imaging with the positron emission tomography (PET) agent Pittsburgh compound B (PiB) can detect vascular β-amyloid (Aβ) in the essentially pure form of cerebral amyloid angiopathy associated with the Dutch-type hereditary cerebral amyloid angiopathy (D-CAA) mutation.
Methods: PiB retention in a cortical composite of frontal, lateral, and retrosplenial regions (FLR) was measured by PiB-PET in 19 D-CAA mutation carriers (M ; 13 without neurologic symptoms, 6 with prior lobar intracerebral hemorrhage) and 17 mutation noncarriers (M ). Progression of PiB retention was analyzed in a subset of 18 serially imaged individuals (10 asymptomatic M , 8 M ). We also analyzed associations between PiB retention and cerebrospinal fluid (CSF) Aβ concentrations in 17 M and 11 M participants who underwent lumbar puncture and compared the findings to PiB-PET and CSF Aβ in 37 autosomal dominant Alzheimer disease (ADAD) mutation carriers.
Results: D-CAA M showed greater age-dependent FLR PiB retention (p < 0.001) than M , and serially imaged asymptomatic M demonstrated greater longitudinal increases (p = 0.004). Among M , greater FLR PiB retention associated with reduced CSF concentrations of Aβ40 (r = -0.55, p = 0.021) but not Aβ42 (r = 0.01, p = 0.991). Despite comparably low CSF Aβ40 and Aβ42, PiB retention was substantially less in D-CAA than ADAD (p < 0.001).
Interpretation: Increased PiB retention in D-CAA and correlation with reduced CSF Aβ40 suggest this compound labels vascular amyloid, although to a lesser degree than amyloid deposits in ADAD. Progression in PiB signal over time suggests amyloid PET as a potential biomarker in trials of candidate agents for this untreatable cause of hemorrhagic stroke. ANN NEUROL 2019;86:616-625.
Tsai H, Pasi M, Liu C, Tsai Y, Yen R, Chen Y J Stroke. 2025; 27(1):65-74.
PMID: 39916455 PMC: 11834354. DOI: 10.5853/jos.2024.02376.
15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN.
Daniels A, McDade E, Llibre-Guerra J, Xiong C, Perrin R, Ibanez L medRxiv. 2024; .
PMID: 39148846 PMC: 11326320. DOI: 10.1101/2024.08.08.24311689.
Editorial: Cerebral amyloid angiopathy: from bench to bedside.
Sohrabi H, Greenberg S, Whiley L Front Neurosci. 2024; 18:1370352.
PMID: 38379758 PMC: 10877065. DOI: 10.3389/fnins.2024.1370352.
Fluid biomarkers in cerebral amyloid angiopathy.
Savar S, Ma B, Hone E, Jahan F, Markovic S, Pedrini S Front Neurosci. 2024; 18:1347320.
PMID: 38344467 PMC: 10853435. DOI: 10.3389/fnins.2024.1347320.
Clinical considerations in early-onset cerebral amyloid angiopathy.
Banerjee G, Collinge J, Fox N, Lashley T, Mead S, Schott J Brain. 2023; 146(10):3991-4014.
PMID: 37280119 PMC: 10545523. DOI: 10.1093/brain/awad193.